The TIAA CREF Trust Co. FSB MO Boosts Stake in C R Bard Inc (BCR)

The TIAA CREF Trust Co. FSB MO Boosts Stake in C R Bard Inc (BCR)

Several other hedge funds and other institutional investors have also modified their holdings of the company. State Street Corp raised its stake in shares of C R Bard by 5.0% in the fourth quarter. State Street Corp now owns 3,703,576 shares of the medical instruments supplier’s stock valued at $832,035,000 after buying an additional 176,151 shares in the last quarter. Putnam Investments LLC raised its stake in shares of C R Bard by 1.3% in the fourth quarter. Putnam Investments LLC now owns 1,171,703 shares of the medical instruments supplier’s stock valued at $263,235,000 after buying an additional 15,255 shares in the last quarter. APG Asset Management N.V. increased its stake in shares of C R Bard by 22.7% in the first quarter. APG Asset Management N.V. now owns 844,466 shares of the medical instruments supplier’s stock valued at $209,884,000 after buying an additional 156,353 shares during the last quarter. Norges Bank bought a new stake in shares of C R Bard during the fourth quarter valued at $141,560,000. Finally, Old Mutual Global Investors UK Ltd. increased its stake in shares of C R Bard by 82.5% in the first quarter. Old Mutual Global Investors UK Ltd. now owns 528,921 shares of the medical instruments supplier’s stock valued at $131,458,000 after buying an additional 239,150 shares during the last quarter. 86.89% of the stock is owned by institutional investors.

TIAA CREF Trust Co. FSB MO increased its stake in shares of C R Bard Inc (NYSE:BCR) by 16.0% during the first quarter, according to its most recent filing with the SEC. The fund owned 12,168 shares of the medical instruments supplier’s stock after buying an additional 1,677 shares during the period. TIAA CREF Trust Co. FSB MO’s holdings in C R Bard were worth $3,024,000 as of its most recent SEC filing.

C R Bard Inc (BCR) opened at 313.36 on Monday. The firm’s 50-day moving average price is $299.16 and its 200 day moving average price is $250.21. C R Bard Inc has a 12-month low of $203.63 and a 12-month high of $313.56. The stock has a market cap of $22.69 billion, a PE ratio of 39.88 and a beta of 0.63.

C R Bard (NYSE:BCR) last released its quarterly earnings results on Sunday, April 23rd. The medical instruments supplier reported $2.87 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.65 by $0.22. C R Bard had a return on equity of 48.48% and a net margin of 14.31%. The firm had revenue of $938.80 million for the quarter, compared to analyst estimates of $916.15 million. During the same quarter last year, the company posted $2.34 earnings per share. The business’s revenue was up 7.5% on a year-over-year basis. Analysts anticipate that C R Bard Inc will post $11.78 EPS for the current year. The business also recently declared a quarterly dividend, which was paid on Friday, May 12th. Investors of record on Monday, May 1st were issued a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.33%. The ex-dividend date was Thursday, April 27th. C R Bard’s dividend payout ratio is currently 14.77%.

C R Bard (NYSE:BCR) last released its quarterly earnings results on Sunday, April 23rd. The medical instruments supplier reported $2.87 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.65 by $0.22. C R Bard had a return on equity of 48.48% and a net margin of 14.31%. The firm had revenue of $938.80 million for the quarter, compared to analyst estimates of $916.15 million. During the same quarter last year, the company posted $2.34 earnings per share. The business’s revenue was up 7.5% on a year-over-year basis. Analysts anticipate that C R Bard Inc will post $11.78 EPS for the current year. BCR has been the subject of several recent research reports. BMO Capital Markets reiterated a “buy” rating and issued a $255.00 price objective on shares of C R Bard in a research report on Tuesday, April 11th. Zacks Investment Research upgraded C R Bard from a “hold” rating to a “buy” rating and set a $276.00 target price for the company in a report on Friday, March 3rd. Morgan Stanley downgraded C R Bard from an “overweight” rating to an “equal weight” rating in a report on Monday, April 24th. Jefferies Group LLC increased their price objective on C R Bard from $237.00 to $317.00 and gave the stock a “hold” rating in a report on Monday, April 24th. Finally, Cowen and Company increased their target price on C R Bard from $240.00 to $317.00 and gave the stock a “market perform” rating in a research note on Monday, April 24th. Twelve analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $264.92.

In other C R Bard news, VP Frank Lupisella, Jr. sold 3,622 shares of C R Bard stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $304.00, for a total value of $1,101,088.00. Following the sale, the vice president now owns 10,139 shares of the company’s stock, valued at approximately $3,082,256. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.97% of the company’s stock. C R Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “BCR”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment